US OptionsDetailed Quotes

HUMA241220C7500

Watchlist

0.18
-0.02-10.00%

15min DelayClose Dec 3 16:00 ET

0.29High0.15Low

Humacyte Stock Discussion

102875548

Nov 29 15:26

$Humacyte (HUMA.US)$
🏄🏼‍♂️🏄🏼‍♂️🏄🏼‍♂️

102875548

Nov 26 08:49

$Humacyte (HUMA.US)$
🥱🥱🥱😴😴😴

102875548

Nov 25 08:44

$Humacyte (HUMA.US)$
🚀🚀🚀 USD 6 Stsge 3 results going to be announced... parking.

Jaguar8

Nov 24 20:46

MY MONDAY WATCHLIST. These are the stocks with POSSIBLE run between 20% and up based on news, chart, or promotion.

NOTE: NFA. Do not open position without buy pressure, volume. Check indicators, chart.
I see more Quantum play this week.
$Quantum (QMCO.US)$ AWS launched QuantumEmbark. Up after hours. Small float. 0 shares LTB.
$Arqit Quantum (ARQQ.US)$ AWS launched Quantum Embark.Increased market cap which translates to stock increasing in stock value and increased confidence in the stock. Low floa...

Quantum Computing Boom: How AWS is disrupting the AI industry?

Trytosaveabit

Nov 22 07:06

Watching

$Humacyte (HUMA.US)$ Humacyte To Present Phase 3 Results Comparing Efficacy And Safety Of Tissue-Engineered Vessel To AV Fistulas In End-Stage Renal Disease Patients At VEITH Symposium On November 23, 2024
Benzinga· 3 mins ago

Jaguar8

Nov 22 07:00

NEWS

$Humacyte (HUMA.US)$
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)
Humacyte (Nasdaq: HUMA) announced it will present Phase 3 results comparing the efficacy and safety of its acellular tissue engineered vessel (ATEV™) with autologous AV fistulas in end-stage renal disease patients. The presentation will be delivered by Dr. Charles Keith Ozaki at the 51s...

104983812

Nov 19 09:17

$Humacyte (HUMA.US)$ shd i sell this shit stock ?

Trytosaveabit

Nov 18 07:07

Update

$Humacyte (HUMA.US)$ Humacyte Presents Preclinical Results Of Small-Diameter ATEV For Coronary Artery Bypass Grafting At American Heart Association's Scientific Sessions 2024; SdATEV Was Observed To Recellularize With Host Cells And Remodel To Effectively Reduce The Initial Size Mismatch Between The SdATEV And The Animal's Native Artery
– sdATEVs maintained sustained patency throughout the six-month study –
– sdATEV was observed to recellularize with host cells and remodel to effectively re...

convivial Penguin_29

Nov 8 18:14

Share Your Profit/Loss

104983812

Nov 8 09:38

$Humacyte (HUMA.US)$
what happened? the earnings suck but now the stock is rising

No comment yet